T. Rowe Price Associates’s Arcosa ACA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30M Buy
282,398
+154,201
+120% +$17.5M ﹤0.01% 933
2025
Q4
$13.6M Buy
128,197
+81,103
+172% +$8.19M ﹤0.01% 1161
2025
Q3
$4.41M Buy
47,094
+2,236
+5% +$208K ﹤0.01% 1433
2025
Q2
$3.89M Buy
44,858
+4,800
+12% +$402K ﹤0.01% 1358
2025
Q1
$3.09M Buy
40,058
+1,889
+5% +$173K ﹤0.01% 1413
2024
Q4
$3.69M Sell
38,169
-2,348
-6% -$236K ﹤0.01% 1377
2024
Q3
$3.84M Buy
40,517
+90
+0.2% +$7.86K ﹤0.01% 1378
2024
Q2
$3.37M Buy
40,427
+1,428
+4% +$119K ﹤0.01% 1359
2024
Q1
$3.35M Buy
38,999
+1,761
+5% +$143K ﹤0.01% 1346
2023
Q4
$3.08M Buy
37,238
+1,947
+6% +$143K ﹤0.01% 1360
2023
Q3
$2.54M Buy
35,291
+98
+0.3% +$7.43K ﹤0.01% 1374
2023
Q2
$2.67M Buy
35,193
+575
+2% +$38.7K ﹤0.01% 1377
2023
Q1
$2.19M Buy
34,618
+1,046
+3% +$61.4K ﹤0.01% 1434
2022
Q4
$1.82M Buy
33,572
+145
+0.4% +$8.61K ﹤0.01% 1502
2022
Q3
$1.91M Sell
33,427
-13,037
-28% -$723K ﹤0.01% 1478
2022
Q2
$2.16M Sell
46,464
-724
-2% -$37.9K ﹤0.01% 1586
2022
Q1
$2.7M Sell
47,188
-226,729
-83% -$11.7M ﹤0.01% 1592
2021
Q4
$14.4M Sell
273,917
-1,954
-0.7% -$104K ﹤0.01% 1347
2021
Q3
$13.8M Buy
275,871
+12,868
+5% +$667K ﹤0.01% 1380
2021
Q2
$15.4M Buy
263,003
+150,636
+134% +$9.32M ﹤0.01% 1358
2021
Q1
$7.31M Buy
112,367
+63,682
+131% +$3.91M ﹤0.01% 1429
2020
Q4
$2.67M Buy
48,685
+5,698
+13% +$291K ﹤0.01% 1556
2020
Q3
$1.9M Sell
42,987
-18,891
-31% -$830K ﹤0.01% 1563
2020
Q2
$2.61M Sell
61,878
-1,075
-2% -$41.4K ﹤0.01% 1478
2020
Q1
$2.5M Buy
62,953
+10,864
+21% +$459K ﹤0.01% 1453
2019
Q4
$2.32M Buy
52,089
+1,931
+4% +$74.3K ﹤0.01% 1562
2019
Q3
$1.72M Buy
50,158
+223
+0.4% +$7.72K ﹤0.01% 1618
2019
Q2
$1.88M Buy
49,935
+1,525
+3% +$52.2K ﹤0.01% 1614
2019
Q1
$1.48M Buy
48,410
+8,274
+21% +$253K ﹤0.01% 1696
2018
Q4
$1.11M Buy
+40,136
New +$1.1M ﹤0.01% 1759

Other funds holding ACA

T. Rowe Price Associates's ACA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Arcosa (ACA) stake by 120% in Q1 2026, buying an estimated $17.5M and bringing the position to 282,398 shares worth $30M. The position accounts for ﹤0.01% of the portfolio, ranked #933.

T. Rowe Price Associates first reported a position in ACA in Q4 2018 and has held it in 30 quarters since. 372 funds tracked by Wall St. Rank hold ACA as of Q1 2026.

  • T. Rowe Price Associates held 282,398 shares of Arcosa worth $30M as of Q1 2026.
  • T. Rowe Price Associates bought 154,201 Arcosa shares in Q1 2026, an estimated $17.5M.
  • Arcosa made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #933 holding.
  • T. Rowe Price Associates first reported a position in Arcosa in Q4 2018 and has held it in 30 quarters since.
  • 372 funds tracked by Wall St. Rank held Arcosa as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.